138 related articles for article (PubMed ID: 20817742)
1. Population pharmacokinetics of meropenem in burn patients.
Doh K; Woo H; Hur J; Yim H; Kim J; Chae H; Han S; Yim DS
J Antimicrob Chemother; 2010 Nov; 65(11):2428-35. PubMed ID: 20817742
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
Lomaestro BM; Drusano GL
Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea.
Lee DG; Choi SM; Shin WS; Lah HO; Yim DS
Int J Antimicrob Agents; 2006 Oct; 28(4):333-9. PubMed ID: 16942864
[TBL] [Abstract][Full Text] [Related]
4. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
[TBL] [Abstract][Full Text] [Related]
5. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate.
Bradley JS; Sauberan JB; Ambrose PG; Bhavnani SM; Rasmussen MR; Capparelli EV
Pediatr Infect Dis J; 2008 Sep; 27(9):794-9. PubMed ID: 18645546
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients.
Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Oct; 46(10):1171-8. PubMed ID: 16988206
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients.
Du X; Li C; Kuti JL; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2006 Jan; 46(1):69-75. PubMed ID: 16397286
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S; Punyo J
Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modelling response of Pseudomonas aeruginosa to meropenem.
Tam VH; Schilling AN; Poole K; Nikolaou M
J Antimicrob Chemother; 2007 Dec; 60(6):1302-9. PubMed ID: 17913722
[TBL] [Abstract][Full Text] [Related]
11. Considerations of meropenem dosage for bacterial meningitis based on pharmacodynamics in cerebrospinal fluid.
Ikawa K; Morikawa N; Ikeda K; Tsumura R; Shibukawa M; Iida K; Kurisu K
Int J Antimicrob Agents; 2008 Jul; 32(1):96-8. PubMed ID: 18539005
[No Abstract] [Full Text] [Related]
12. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
13. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients.
Cheatham SC; Kays MB; Smith DW; Wack MF; Sowinski KM
Pharmacotherapy; 2008 Jun; 28(6):691-8. PubMed ID: 18503396
[TBL] [Abstract][Full Text] [Related]
15. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapy.
Santos Filho L; Eagye KJ; Kuti JL; Nicolau DP
Clin Microbiol Infect; 2007 Jun; 13(6):579-85. PubMed ID: 17331121
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations.
Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S
Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic properties of meropenem.
Nicolau DP
Clin Infect Dis; 2008 Sep; 47 Suppl 1():S32-40. PubMed ID: 18713048
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa.
Harashima S; Kondo H; Nabeshima A; Shimoda M; Yamaji K; Horiuchi T; Shimono N; Ikematsu H
J Infect Chemother; 2008 Jun; 14(3):219-22. PubMed ID: 18574658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
20. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
